ABSTRACT
Objective The objective of this study was to investigate the role and molecular mechanism of AtractylenolideⅠin the progression of lung cancer. Methods qRT-qPCR and immunohistochemistry were used to detect the expression of TLR4 and MyD88 at levels of mRNA and protein in lung cancer and adjacent tissues. Transwell and MTT assays were used to detect effects of at-ractylenolide I(100 μM)on the invasion,migration and proliferation of A549 cells. Western blot was also used to detect the effect of atractylenolide I on the expression of TLR4 and MyD88 proteins. Results The expression of TLR4 and MyD88 at levels of mRNA and protein was highly expressed in lung cancer tissues when compared to adjacent tissues(P<0. 05). Compared with the control group,the invasion ability of A549 cells in the Atractylenolide I group was significantly decreased,and the proliferative activity was in-hibited(P<0. 05). Atractylenolide I inhibited the expression of TLR4 and MyD88 protein in A549 cells( P<0. 05). Conclusion
ABSTRACT
Objective To explore the influence of arsenous acid on hepatic and colonic cancer cell lines BEL-7402 and HT-29 .The effect of bortezomib combined with chemotherapeutic medicine and the optimal combination plan of them were also investigated .Methods We detected cell proliferation by MTT to get the inhi-bition rate of two cell lines and further to determine IC 50 ( inhibitory concentration50%) of 5-Fu,oxaliplatin or arsenous acid;preincubated cancer cells for 2 h、4 h or 8 h by bortezomib .Chemotheraputic medicine were com-bined respectively .The cell proliferation and apoptosis were analysed by MTT ,TUNEL and Annexin V -PI.Re-sult s The 24 h inhibition rate of arsenous acid to BEL -7402 and HT-29 was:0.59 ±0.09、0.71 ±0.12 re-spectively;the IC50 of 5 -Fu,Oxaliplatin or arsenous acid to BEL -7402 was:5.33 ±0.07 mg/L,28.73 ± 0.72 mg/L,25.93 ±4.05 mg/L, while to HT -29 was:7.33 ±1.13 mg/L、53.94 ±1.23 mg/L,21.93 ± 2.05 mg/L.Both inhibition rate and apoptosis rate were enhanced when chemotheraputic medicine was combined with bortezomib .Co nclusion Arsenous acid can inhibit the growth of cancer cells obviously;the susceptibility of each chemotherapy medicine can be strengthened significantly when it is combined with bortezomib ,P<0.05.
